Sound Pharmaceuticals Completes Enrollment in Phase 3 SPI-1005 Study for Ménière’s Disease

Sound Pharmaceuticals has completed enrollment in its second Phase 3 open-label study of SPI-1005, an investigational oral anti-inflammatory drug with FDA Breakthrough Therapy Designation, for the treatment of Ménière's disease.